Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters. by Nazarov, A.A. et al.
Synthesis and characterization of a new
class of anti-angiogenic agents based on
ruthenium clusters
Alexey A. Nazarov1,2, Mathurin Baquie´1, Patrycja Nowak-Sliwinska1,3, Olivier Zava1, Judy R. van
Beijnum4, Michael Groessl1, Danielle M. Chisholm5, Zohrab Ahmadi5, J. Scott McIndoe5,
Arjan W. Griffioen4, Hubert van den Bergh1 & Paul J. Dyson1
1Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland,
2Department of Chemistry, Moscow State University, Leninskie Gory, 119991, Moscow, Russia, 3Urology Department, University
Hospital (CHUV) CH-1011, Lausanne, Switzerland, 4Angiogenesis Laboratory, Department of Medical Oncology, VU University
Medical Center 1081 HV, Amsterdam, The Netherlands, 5Department of Chemistry, University of Victoria, P.O. Box 3065, Victoria,
British Columbia V8W 3V6, Canada.
New triruthenium-carbonyl clusters derivatized with glucose-modified bicyclophosphite ligands have been
synthesized. These compounds were found to have cytostatic and cytotoxic activity and depending on the
number of bicyclophosphite ligands, and could be tuned for either anti-cancer or specific anti-angiogenic
activity. While some compounds had a broad cellular toxicity profile in several cell types others showed
endothelial cell specific dose-dependent anti-proliferative and anti-migratory efficacy. A profound
inhibition of angiogenesis was also observed in the in vivo chicken chorioallantoicmembrane (CAM)model,
and consequently, these new compounds have considerable potential in drug design, e.g. for the treatment of
cancer.
T
he development of metal-based anti-cancer compounds has traditionally focused on cytotoxic platinum-
based compounds, several of which are widely applied in the clinic1–3. In recent years, however, there
has been increasing interest in the development of ruthenium-based anticancer compounds that appear
to operate via very different mechanisms, as compared to the clinically used platinum drugs4–6. Indeed,
ruthenium complexes tend to be less cytotoxic towards cancer cells in vitro and their propensity to bind
DNA is lower. Two ruthenium compounds, indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]),
termed KP10197, and imidazolium trans-[tetrachloro(dimethylsulfoxide)(1H-imidazole)ruthenate(III)]),
termed NAMI-A8, are presently in phase II clinical trials, the latter compound showing both anti-metastatic
and anti-angiogenic activity in preclinical models. We recently found that a very different type of ruthenium
compound, organometallic ruthenium(II) complexes, [Ru(g6-arene)Cl2(PTA)] (arene 5 toluene and p-
cymene, PTA 5 1,3,5-triaza-7-phosphaadamantane), also exhibit anti-metastatic9 and anti-angiogenic10
properties. Indeed, the effect of these small molecules was at least equivalent to that of sunitinib/SutentH
or sorafenib/NaxavarH, clinically used tyrosine kinase inhibitors with anti-angiogenic properties11. The
promising activities of the ruthenium compounds dictate the need for information on their biomolecular
targets and suggests a clinical relevance. In this respect a large number of ruthenium compounds have been
evaluated in vitro although classical in vitro cytotoxicity screens have proven, in the past, not to be particu-
larly informative of in vivo activity4,12.
While most ruthenium-based compounds that have been evaluated as putative anti-cancer agents are mono-
nuclear species with the central ruthenium ion in the 21 or 31 oxidation states, a few studies describing the in
vitro activity of ruthenium(0) and osmium (0) clusters have been published13,14. Many of these cluster compounds
contain carbonmonoxide (CO) and/or other ligands, and notably, the biological importance of CO as an essential
mediator of numerous effects, including anti-inflammatory- and anti-proliferative activity, has recently been
reported15. Indeed, a number of CO releasing compounds show promising pharmacological properties16–18.
Consequently, we decided to determine the anti-angiogenic activity of the family of ruthenium-carbonyl clusters
in a series of in vitro assays and based on highly promising results we conducted an in vivo study with these cluster
compounds.
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Results
Triruthenium dodecacarbonyl, Ru3(CO)12, was derivatized with a
glucose-modified bicyclophosphite ligand19,20 affording four differ-
ent compounds (1 – 4, Figure 1). The procedure involves treatment
of Ru3(CO)12 with trimethylamine-N-oxide (that oxidatively
removes CO ligands in a stoichiometric fashion generating a vacant
coordination site) in CH2Cl2 containing the bicyclophosphite ligand.
By varying the stoichiometry of the reagents (see Experimental
Section for details) substitution of up to four carbonyl ligands by
the phosphite can be achieved. Chromatographic separation of the
products is required to obtain analytically pure material and 4 is the
only obtained as a side-product.
The 1H and 13C signals of the bicyclophosphite ligand(s) in the
NMR spectra of 1 – 4 change slightly upon coordination to the
ruthenium cluster core. More significant changes are observed in
the 31P NMR spectra with singlets observed at d 149.9 ppm for 1
and at d 150.3 for 3 (cf. the free ligand d 5 119.0). The 31P NMR
spectrum of 2 is more complicated due to dynamic behavior and
appears as a set of two (broad) singlets at room temperature (d 5
149.7 and 148.4), which splits to three singlet resonances at 275uC
(such behavior has been noted for related complexes)21,22. The 31P
NMR spectrum of 4 is highly complicated as each bicyclophosphite
ligand is in a unique environment and they are also undergoing
dynamic processes on the NMR timescale.
Electrospray ionization mass spectrometry (ESI-MS) was used to
characterize 1 – 3, and for each cluster a parent ion was observed
corresponding the intact compound with an associated sodium
cation, i.e. [M1Na]1. In addition, in order to delineate the relative
stability of the ligands, i.e. the carbonyl ligands versus the bicyclo-
phosphite ligands, energy-dependent ESI-MS experiments23 were
conducted (Figure 2). These revealed that the CO ligands dissociate
in preference to the bicyclophosphite ligands in 1 – 3. Interestingly,
the greater the number of bicyclophosphite ligands in the cluster, the
greater the proportion of CO ligands that are lost before ligand
decomposition and/or dissociation takes over, despite the fact that
these clusters have fewer CO ligands to beginwith. Thus, 1 has 11 CO
ligands and loses only five COs before dissociation of the bicyclopho-
sphite ligand commences, whereas 3 has nine CO ligands and seven
of them are lost before decomposition of the bicyclophosphite
ligands begins to compete with CO loss. The clusters are likely sta-
bilized by the ability of the bicyclophosphite ligands to fold back and
bind to the vacant coordination sites as CO ligands are successively
removed and, hence, 1 does this least effectively as it has only one
bicyclophosphite ligand. At 45 V and above, bicyclophosphite ligand
dissociation (green) and bicyclophosphite ligand decomposition
(blue) are observed as competitive processes. The spectrum at the
top is a summation of the 150 spectra used to generate the contour
map. Disappearance of ion intensity at high collision energy is due to
dissociation of Na1 (responsible for the charge on the complex).
While extensive CO ligand loss can be induced in the gas phase in
aqueous solution, 1 – 3 aremoderately soluble and stable for days. No
signs of hydrolysis or decomposition were observed by 31P NMR
spectroscopy. The logPo/w values of 1 – 3 were determined (see
Table 1).
Compounds 1 – 3 were initially screened for activity to inhibit cell
growth in four human cancer cell lines and an endothelial cell line
(Table 1) using a proliferation assay. Clusters 1 and 2 were similarly
active on the different cells, with IC50 values in the range 0.1 –
0.8 mM, after a 72 hour exposure time. In contrast, 3 is not cytotoxic
in the four cancer cell lines (IC50. 300 mM), but shows cytotoxicity
towards the ECRF24 endothelial cells (ca. 60 mM). Intracellular
uptake of ruthenium was also determined (Table 1) with uptake of
1 being approximately a thousand times higher than that of 3, indi-
cating that the differences in LogPo/w values do not entirely account
for differences in uptake. Upon treatment with 1 or 2 (60 mM) a
significant sub-population of A2780 cells underwent apoptosis.
The least cytotoxic compound 3 did not induce apoptosis
(Table 2), neither in endothelial, nor cancer cells, but led to cell cycle
arrest in the G0/G1 phase.
Figure 1 | Synthesis of ruthenium-carbonyl clusters with the 3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D -glucofuranoside ligand.
Figure 2 | Positive-ion energy-dependent ESI-MS of [2 1 Na]1 as a
representative example.
www.nature.com/scientificreports
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The process of angiogenesis depends, next to proliferation, also on
migration of endothelial cells. Therefore the compounds were tested
in a cell migration assay. This was performed on cultures of ECRF24
human endothelial cells and invasive MDA-MB-231 human breast
adenocarcinoma cells (Figure 3). Cluster 1 did not affect ECRF24
mobility at the tested concentration range (0.1–62 mM), but signifi-
cantly inhibited the mobility of MDA-MB-231 cells, already at
0.1 mM (by ca. 60%), and by 95% at 3 mM (Figure 3A, *P , 0.05).
Interestingly, 3 did not affect the mobility of the adenocarcinoma
cells, even concentrations of up to 50 mM were ineffective, while the
ECRF24 cells were more sensitive to this compound. Migration was
inhibited by approximately 30% at 60 mM (Figure 3B, *P , 0.05).
Figure 3C shows examples of thewound images of confluent ECRF24
layers before (T 5 0 h) and after 7 hours incubation (T 5 7 h) with 3
(60 mM).
To check for potential anti-angiogenic activity in vivo, 1 and 3
were tested in the chicken embryo chorioallantoicmembrane (CAM)
assay. The clusters were topically applied daily for 3 days starting
treatment at embryo development day 6 (EDD6), when vasculariza-
tion of the membrane starts to increase exponentially. The drugs
were applied at 150 mM concentration as homogeneous solutions
in 0.9% NaCl. Figure 4A shows typical fluorescence angiographies
taken at EDD9 for the control and treated CAMs. In the control
embryos, the capillary plexus waswell developed and a homogeneous
vascularization was observed (Figure 4A). In contrast, neovascular-
ization was inhibited after treatment with the clusters. A clear and
strong effect was observed with 3, indicated in Figure 4A as black
avascular zones in angiographies (red arrowheads). A lesser effect
was seen for 1. This was quantified by digital assessment of the
number of branching points per mm2 and the mean mesh size
(102 mm2), which revealed statistically significant differences (*P ,
0.05). The number of branching points/mm2 dropped from 2019 6
45 (control) to 1212 6 61 for 1 and 428 6 70 for 3 (Figure 4B). The
mean mesh size increased from 5.4 6 0.2 (control) to 8.9 6 0.3 for 1
and 31.0 6 15.0 for 3 (102 mm2, Figure 4C).
Discussion
In order to obtain physiologically compatible triruthenium cluster
compounds, triruthenium dodecacarbonyl, Ru3(CO)12, was deriva-
tized with a glucose-modified bicyclophosphite ligand19,20 affording 1
– 4. All four compounds were fully characterized by spectroscopic
and analytical methods. It was found that the bicyclophosphite
ligand significantly alters the chemical and biological properties of
compounds, e.g. influencing solubility, uptake, and biomolecular
interactions24,25–28. Compounds 1 – 3 are moderately soluble and
stable in aqueous solutions for days (no signs of hydrolysis or decom-
position were observed). This behavior differs to that of most
ruthenium(II) and ruthenium(III) compounds that rapidly undergo
hydrolysis. In the gas phase CO loss may be induced from the cluster
core with a strong preference for loss of CO relative to the bicyclo-
phosphite ligand(s) as determined by ESI-MS. The overall behavior
observed is in stark contrast to the clusters Ru3(CO)122n(PPh3)n (n
5 1–3), where the triphenylphosphine ligands are the first to dis-
sociate from the clusters under energetic fragmentation conditions29.
The logPo/w values of 1 – 3 are as expected, as the number of bicy-
clophosphite ligands increases the compounds become increasingly
hydrophilic, see Table 1.
The number of bicyclophosphite ligands attached to the cluster
core significantly influences the biological activity of compounds 1 –
3. Clusters 1 and 2 were similarly cytotoxic on the different cancer
cell lines (IC50 values in the range 0.1 – 0.8 mM), whereas 3 is not
cytotoxic in the four cancer cell lines (IC50 .300 mM), but is mod-
erately cytotoxic towards the endothelial cells (ca. 60 mM). These
results match closely with the LogPo/w values (Table 1); the most
lipophilic compound, 1, is also the most cytotoxic, and 3, which is
the least cytotoxic compound, is also the least lipophilic. Intracellular
uptake of ruthenium was also determined (Table 1) with uptake of 1
being approximately a thousand times higher than that of 3. The
differences in LogPo/w values do not entirely account for differences
in uptake. It is suggested that the mechanism of anti-proliferative
activity of the compounds is only partly based on apoptosis induction
(Table 2). Compound 1 at high concentrations showed more pro-
nounced apoptosis in endothelial cells (ECRF24) compared to cancer
cells (A2780). Compound 2, which showed amodest anti-angiogenic
effect, shows essentially equivalent apoptosis in both cell lines.
Compound 3, showing a clear anti-angiogenic activity in vivo, arrests
the cell cycle in the G1/G0 phase leading to senescence, and not
leading to direct apoptosis.
The compounds were tested in a cell migration assay on ECRF24
human endothelial cells and invasive MDA-MB-231 human breast
adenocarcinoma cells. The resulting data show that two hallmarks of
angiogenesis, namely endothelial cell proliferation and, to the lesser
extent, migration are inhibited by 3, while these effects were absent in
tumor cells. Consequently the anti-angiogenic activity of 1 and 3was
tested in vivo in the chicken embryo chorioallantoic membrane
(CAM) assay. Under the applied conditions neovascularization
was inhibited after treatment with the clusters with a clear and strong
effect observed with 3 (Figure 4A) and a lesser effect was seen for 1.
Table 1 | Cytotoxicity towards A2780, A2780cisR, HT29 and A549 cancer cells, and ECRF24 endothelial cells, and intracellular uptake in
A2780 cells and logPo/w values of 1 – 3. Errors represent the standard error of the mean (SEM)
IC50 (mM 6 SEM)
Intracellular
uptake, pM
Cell line
Compound A2780 A2780cisR HT29 A549 ECRF24 A2780 LogPo/w
1 0.095 6 0.03 0.135 6 0.01 0.33 6 0.11 0.49 6 0.09 0.43 6 0.21 45761 6 595 7.55
2 0.83 6 0.25 0.57 6 0.23 0.58 6 0.29 0.12 6 0.05 0.17 6 0.09 1356 6 30 6.59
3 .300 .300 .300 .300 59.88 6 9.92 3.1 6 0.5 6.26
{Untreated A2780 cells 5 19.05 6 0.78%.
Table 2 | Cell-cycle alterations were evaluated using PI-FACS ana-
lysis and a representative result is presented in ECRF24 andA2780
cells Apoptosis rates were measured by PI-FACS analysis (n 5 4)
after 72 h incubation with two concentrations of drugs 1–3
Compound
(mM) ECRF24 A2780
G1/G0 G2/M Apoptosis G1/G0 G2/M Apoptosis
1 (0.17) 54.6 27.3 6.16 68.0 13.5 0.2
1 (0.43) 7.9 2.5 44.8 50.8 28.9 8.8
2 (0.06) 15.1 4.5 45 16.0 11.2 47.1
2 (0.17) 20.7 7.4 34.7 22.4 19.2 26.5
3 (20) 56.2 30.8 3.2 63.3 9.2 0.5
3 (60) 61.6 25.6 3.2 61.7 32.7 0.3
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The results show a clear inhibition of angiogenesis, especially for 3,
which matched the effects observed in endothelial proliferation and
migration assays. Interestingly, the anti-angiogenic activity of 3
clearly outperformed the FDA-approved small-molecule angiogen-
esis inhibitors sorafenib (Bayer and Onyx Pharmaceuticals)30,11 and
sunitinib (Pfizer)31. These approved drugs exert angiogenic inhibi-
tion via multiple targets including Raf serine/threonine kinases, vas-
cular endothelial growth factor receptor tyrosine kinases: VEGFR-1/
VEGFR-2/VEGFR-3/platelet-derived growth factor receptor b,
PDGFR-b (sorafenib); or VEGFRs/PDGFR-b/c-KIT/FLT-3 (suniti-
nib)32. For comparison, at 150 mM, the number of branching point/
mm2 values are approximately 1100 for sorafenib and 1450 for suni-
tinib, compared to 428 for 3.
To conclude, a highly selective anti-angiogenic triruthenium clus-
ter, 3, is reported. Since clusters represent molecular species inter-
mediate between single metal complexes and metal nanoparticles
they occupy a unique position for medicinal applications. Com-
pared to mononuclear complexes, far more diversity can be added
to a cluster framework. In comparison to nanoparticles, rational
synthetic methods can be used to produce precisely designed mole-
cular structures. Indeed, it was shown that slight changes to the
peripheral ligands completely switched the biological activity of the
cluster. Although the target (or targets) of these clusters remains to be
delineated, the in vivo results demonstrate that 3 exhibits an intrinsic
angiostatic activity of high clinical relevance.
Methods
Compound characterization. 1H (400.13 MHz), 31P{1H} (161.98 MHz) and 13C{1H}
(100.62 MHz) NMR spectra were recorded at 25uC on a Bruker Avance II 400
Spectrometer and referenced to residual solvent peaks (CDCl3 1H 7.26,13C{1H} 77.16;
CD2Cl2 1H 5.30, 13C{1H} 53.84; d6-DMSO 1H 2.50, 13C{1H} 39.52) or reported relative
to 85% H3PO4. EDESI-MS spectra were collected on a Micromass Q-Tof micro in
positive ion mode. Log Poctanol/water was determined using a literature method33, and
the correlation between log Kw and log P was established using compounds with
known log P values (4-methoxyanilin 0.95,
4-bromanilin 2.26, naphtalene 3.30, tert-butylbnzene 4.11, pyrene 4.50).
Synthesis of Ru3(CO)11(3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-
glucofuranoside) 1. A solution of 3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-
D-glucofuranoside (78 mg, 0.031 mmol), in CH2Cl2 5 mL was added to a solution of
Ru3(CO)12 (200 mg, 0.31 mmol) under nitrogen at room temperature. The reaction
mixture was stirred for 5 min and Me3NO (24 mg, 0.031 mmol) was added. The
reaction was stirred for 12 h and the solvent was removed and the compound isolated
by flash chromatography (eluent CH2Cl25Et2O 451). Yield 120 mg (45%), m.p.
125–127uC decomp., elem. anal. calcd (%) for C20H13O17PRu3: C 27.95, H 1.52, P
3.60; found: C 27.67, H 1.22, P 3.99. 1H NMR (400.13 MHz, CDCl3): d 5 6.10
(d, J5 3.8 Hz, 1H;H-1), 5.02 (m, 1H;H-5), 4.63 (m, 1H; H-3), 4.62 (d, J5 3.9Hz, 1H;
H-2), 4.39 (tr, J 5 9.4, 1H; H-6), 4.30 (m, 1H, H-69), 4.22 (m, 1H, H-4), 1.51 (s, 3H,
CH3), 1.36 (s, 3H, CH3) ; 31P{1H} NMR (161.98 MHz, CDCl3): d 5 148.9 ppm. MS
(ESI1): m/z: 885 [M1Na]1.
Synthesis of Ru3(CO)10(3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-
glucofuranoside)2 2. Compound 2 was prepared similar to that of 1 starting from
3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-glucofuranoside
(155 mg, 0.062 mmol), Ru3(CO)12 (200 mg, 0.31 mmol) and Me3NO (70 mg, 0.093
mmol). Yield 178 mg (53%), m.p. 150–151uC decomp., elem. anal. calcd (%) for
C28H16O22P2Ru3: C 31.15, H 2.43, P 5.74; found: C 31.15, H 2.27, P 6.07.1H NMR
(400.13MHz, CDCl3): d5 6.10 (d, J5 3.8Hz, 1H;H-1), 4.98 (m, 1H;H-5), 4.67–4.59
(m, 2H; H-3, H-2), 4.35 (tr, J 5 9.7, 1H; H-6), 4.28 (m, 1H, H-69), 4.20 (m, 1H, H-4),
1.50 (s, 3H, CH3), 1.34 (s, 3H, CH3) ;31P{1H} NMR (161.98 MHz, CDCl3)5 d5 149.7,
148.4 (351) ppm. MS (ESI1): m/z: 1105 [M1Na]1.
Synthesis of Ru3(CO)9(3,5,6-bicyclophosphite-1,2-O-isopropylidene-
a-D-glucofuranoside)3 3. Compound 3 was prepared similar to that of 1 starting
from 3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-glucofuranoside (232 mg,
0.094 mmol), Ru3(CO)12 (200 mg, 0.31 mmol) and Me3NO (95 mg, 1.25 mmol).
Yield 278 mg (57%), m.p. 129-130uC decomp., elem. anal. calcd (%) for
C36H39O27P3Ru3: C 33.27, H 3.02, P 7.15; found: C 33.23, H 2.80, P 7.33. 1H NMR
Figure 3 | Migration inhibition assessment of ECRF24 and MDA-MB-231 cells after exposure to compound 1 and 3. Wound closure in ECRF24
cultures after 7 h of incubation with concentration ranges of 1 (A) and 3 (B). (C) Typical images of the wound at the beginning of the experiment
(culture medium as a control) and after 7 h of incubation with 3, 60 mM. Error bars represent standard error of the mean. *P , 0.05.
www.nature.com/scientificreports
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(400.13 MHz, CDCl3): d 5 6.10 (d, J 5 3.8 Hz, 1H; H-1), 4.96 (m, 1H; H-5),
4.64- 4.57 (m, 2H; H-3, H-2), 4.33 (tr, J 5 9.6, 1H; H-6), 4.26 (m, 1H, H-69),
4.18 (m, 1H, H-4), 1.50 (s, 3H, CH3), 1.34 (s, 3H, CH3) ;31P{1H} NMR (161.98 MHz,
CDCl3): d 5 150.3 ppm. MS (ESI1): m/z: 1325 [M1Na]1.
Synthesis of Ru3(CO)8(3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-
glucofuranoside)4 4. Compound 4 was isolated as by-product in the synthesis of 2
and 3. M.p. 160-165uC decomp., elem. anal. calcd (%) for C44H52O32P4Ru3: C 34.77,
H 3.45, P 8.15; found: C 34.45, H 3.29, P 8.10. 31P{1H} NMR (161.98 MHz, CDCl3): d
5 153.1-148.3 (multiplet) ppm.MS (ESI1): m/z: 1325 [M1Na]1.
Cell culture. Human A2780 and A2780cisR ovarian carcinoma cells were obtained
from the European Centre of Cell Cultures (ECACC, UK), Human colon
adenocarcinoma cells (HT29) were obtained fromATCC (France). Adenocarcinomic
human alveolar basal epithelial cells (A549) and human breast adenocarcinoma cells
(MDA-MB-231) were provided by the Institute of Pathology, CHUV, Lausanne,
Switzerland. Human A2780 and A2780cisR ovarian carcinoma cells were routinely
grown in RPMI 1640 medium supplemented with GlutaMAX (Gibco), heat-
inactivated fetal calf serum (FCS, Sigma, USA) (10%) and antibiotics (Penicillin/
Streptomycin) at 37uC and CO2 (5%). HT29 and A549 cells were cultured in similar
conditions except that RPMI 1640 was replaced by DMEM medium (Life
Technologies, Carlsbad, USA). Immortalized human umbilical vein endothelial
ECRF24 cells were provided by the Angiogenesis Laboratory (VUMC, The
Netherlands) and were cultured in gelatin-coated flasks; RPMI 1640 culture medium
containing 10% heat-inactivated human serum (Sigma, USA), 10% FCS, GlutaMAX
and antibiotics, as described previously10.
Cell proliferation inhibition. Cytotoxicity was determined as described previously34
by the colorimetricMTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (Fluka) microculture assay on compounds freshly dissolved in DMSO
(Sigma-Aldrich, Buchs, Switzerland) at the required concentration and sequentially
diluted in complete growth medium (max 0.5% of DMSO), and incubated with cells
for 72 h.
Apoptosis assay. ECRF24 or A2780 cells were seeded on 6-well plates (2 3 105 cells/
well) and grown 24 hours in complete medium before treatment. Compounds 1–3
were freshly dissolved inDMSO, diluted in completemedium and added to the cells at
the final concentrations indicated in Table 2. After incubation for 72 h apoptosis was
measured by flow cytometric determination of subdiploid cells after DNA extraction
and subsequent staining with propidium iodide (PI) as described previously10. Briefly,
cells were harvested and subsequently fixed in 70% ethanol at 220uC. After 2 h the
cells were re-suspended in DNA extraction buffer (45 mM Na2HPO4, 2.5 mM citric
acid, and 1% Triton X-100, pH 7.4) for 20 min at 37uC. PI was added to a final
concentration of 20 mg/mL and log scale red fluorescence was analyzed on a
FACSCalibur (BD Biosciences, NJ, U.S.).
Total ruthenium uptake. For evaluation of the cell uptake, cells were seeded in six-
well plates and grown to approximately 70% confluency and incubated with the
clusters 1–3 at a concentration of 60 mM for 5 h. At the end of the incubation period,
cells were rinsed twice with 2.0 mL of PBS, detached by adding 0.5 mL of enzyme free
cell dissociation solution (Millipore, Switzerland), and collected by centrifugation. All
samples were digested in ICP-MS-grade concentrated hydrochloric acid (Sigma
Aldrich, Switzerland) for 3 h at room temperature and filled to a total volume of 8.0
mLwith ultrapure water. Indiumwas added as an internal standard at a concentration
of 0.5 ppb. Determinations of total metal contents were achieved on an Elan DRC II
ICP-MS instrument (Perkin-Elmer, Switzerland) equipped with a Meinhard
nebulizer and a cyclonic spray chamber. The ICP-MS instrument was tuned daily
using a solution provided by the manufacturer containing 1 ppb of each Mg, In, Ce,
Ba, Pb, and U. External standards were prepared gravimetrically in an identical
Figure 4 | Anti-angiogenic activity of 1 and 3. (A) Angiographic images of the developmental CAM (EDD9) treated with 0.9%NaCl (control) and 1 and
3 (150 mM/day). The vasculature is visualized by FITC-dextran fluorescence angiography (25 mg/kg, 20 kDa, lex 5 470 nm, lem 5 520 nm).
Scale bar 200 mm. Red arrows indicate the avascular zones. Quantification of digital analysis of the fluorescence angiography images: number of
branching points (mm2) (B) and mean mesh size (102 mm2) (C) as markers of vessel density for CAM. *P , 0.05 was considered to be statistically
significant. Error bars represent standard error of the mean.
www.nature.com/scientificreports
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matrix to that of the samples (with regard to internal standard and hydrochloric acid)
with single element standards (CPI International, The Netherlands).
Wound Assay (Migration). Themigration capability of cells was measured using the
wound assay10. Briefly, human breast adenocarcinoma (MDA-MB-231) cells and
endothelial cells ECRF24 cultures were grown to confluence and cells were labeled
with calcein AM (Molecular Probes, C3100MP, Carlsbad, USA) for 15 min (1:2000,
Molecular Probes), and ‘‘scratch wounds’’ (with an approximate width of 350 mm)
were made in the monolayer by removing cells with a sterile scratch tool (Peira
Scientific Instruments, Belgium). Cultures were washed with PBS, and the medium
was replaced by fresh medium and incubated with or without Ru-carbonyl clusters.
Plates were scanned using an Acumen eX3 laser scanner cytometer (TTP LabTech
Ltd., UK) to acquire images for computational analysis of scratch sizes using UGR
Scratch Assay 6.2 software (DCI Labs, Peira Scientific Instruments, Belgium).
Developmental CAM and Quantification of the Anti-angiogenic Response. Anti-
angiogenic efficacy of the Ru-carbonyl clusters was tested in the physiologically
developing chicken embryo chorioallantoic membrane (CAM) model between
embryo development days (EDDs) 6 and 9. Ru-carbonyl clusters were applied
topically (150 mM, 3 3 20 ml), at EDDs 6, 7 and 8. The control eggs were treated with
(3 3 20 ml 0.9% NaCl). At EDD 9, the CAMs were visualized in ovo by means of
FITC-dextran (20 kDa, 20 ml, 25 mg/ml, Sigma-Aldrich) epi-fluorescence
angiography and subsequently analyzed by the image-processing quantification
method described previously35. Briefly, based on the FITC-dextran fluorescence
angiography, the skeleton of the vascular network is built, and defined descriptors,
i.e., branching points (mm2) and the mean area of the vessel network meshes
(102 mm2) give information on the vascular architecture. 5 to 6 eggs were tested per
condition. Errors bars represent the standard error of the mean.
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